Laura Manca

Mobile has revolutionised everyday life and now big pharma is using smartphones and other mobile devices to improve research and development.

 

A personalised vaccine which boosts a patient’s own immune system has nearly doubled the number of women surviving ovarian cancer by two years.

Following an earlier negative decision, NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.

Rubraca (rucaparib), already approved as a treatment for BRCA positive ovarian cancer, has been approved as a maintenance therapy for ovarian cancer regardless of BRCA mutation. 

The FDA approves Blincyto (blinatumomab) for patients with B-cell ALL, who are in remission but still have minimal residual disease.

FDA approves Tasigna (nilotinib) for certain pediatric patients with Ph+ CML in chronic phase.

FDA approves Genentech’s Lucentis (ranibizumab injection) syringe for diabetic macular edema and diabetic retinopathy.

FDA expands approval of Adcetris (brentuximab vedotin) for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.

CLL expert explains latest treatment developments in the field.

Expert emphasises healthy lifestyle in prostate cancer care.